Myasthenic crisis: guidelines for prevention and treatment

Area of Science:

• Neurology
• Intensive Care Medicine
• Immunotherapy

Background:

• Myasthenic crisis (MC) necessitates intensive care unit (ICU) admission and prompt, effective treatment.
• Clinical consensus on optimal immunotherapy, such as plasma exchange (PE) versus high-dose immunoglobulin, is lacking for MC in the ICU.
• Treatment choices often depend on institutional preference due to limited comparative clinical trials.

Purpose of the Study:

• To advocate for a primary treatment modality in the acute care setting for myasthenic crisis.
• To emphasize the importance of adjunctive therapies and supportive critical care in managing MC.
• To highlight the need for preventative strategies against myasthenic exacerbations and crises.

Main Methods:

• Review of recent literature on myasthenic crisis management.
• Clinical experience in an intensive care setting.
• Analysis of current therapeutic options and their efficacy.

Main Results:

• Plasma exchange (PE) is proposed as a primary treatment modality for acute myasthenic crisis.
• Corticosteroids and other immunomodulatory medications can support PE therapy.
• Intensive care management of respiratory and bulbar functions is paramount and cannot be replaced by pharmacological treatment.

Conclusions:

• Plasma exchange should be considered the primary treatment for myasthenic crisis in the acute care setting.
• Comprehensive intensive care and supportive management are critical for patient survival and recovery.
• Developing effective maintenance strategies is vital for preventing recurrent myasthenic exacerbations and crises.